Targeted therapy has provided a positive outcome for lung cancer patients with epidermal growth factor receptors (EGFR), anaplastic lymphoma kinase (ALK), ROS proto‐oncogene 1 receptor tyrosine kinase (ROS1) and B‐Raf proto‐oncogene serine/threonine kinase (BRAF) mutations.2, 3, 4, 5. This evidence concerns the gene ALK and lung cancer.